ArticleNature communications2020
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.
Abstract read
In one paragraph
Article in Nature communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed, 2 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Assessing the consistency of iPSC and animal models in cystic fibrosis modelling: A meta-analysis.PloS one · 2022Pooled it
- Current strategies and opportunities to manufacture cells for modeling human lungs.Advanced drug delivery reviews · 2020Pooled it
- Stem cell-based tactics in the remodeling and treatment of intestinal diseases.Stem cell research & therapy · 2026Review
- Protocol for generating iPSC-derived intestinal organoids through dissection to model cystic fibrosis therapies.STAR protocols · 2026Article
- Long isoforms of the COPD risk gene FAM13A orchestrate human lung epithelial development.American journal of respiratory cell and molecular biology · 2026Article
- Generation of biologically responsive colon-like intestinal tissue patches from human induced pluripotent stem cells using a rapid co-differentiation platform.Stem cell research & therapy · 2026Article
- Advances in Internal Organogenesis: Differentiation and Morphogenesis of Human Ventral Cavity Organs.Stem cell reviews and reports · 2026Review
- Polysaccharides and the colon mucus barrier: a review of biophysical interactions and functional impacts.NPJ science of food · 2026Review
- Bidirectional fibrogenic cross-talk revealed in a human iPSC-derived epithelial-mesenchymal co-culture model of pulmonary fibrosis.bioRxiv : the preprint server for biology · 2026Article
- Organoids for disease modeling and treatment: state-of-the-art.Experimental hematology & oncology · 2026Review
- Filovirus infection disrupts epithelial barrier function and ion transport in human iPSC-derived gut organoids.PLoS pathogens · 2025Article
- A simple, efficient technique to make colon crypt gels for 3D models.3D printing and additive manufacturing · 2025Article
- Human intestinal enteroids: Nonclinical applications for predicting oral drug disposition, toxicity, and efficacy.Pharmacology & therapeutics · 2025Review
- In silico modeling of directed differentiation of induced pluripotent stem cells to definitive endoderm.PLoS computational biology · 2025Article
- Human-induced Pluripotent Stem Cell-derived Gut Organoids Recapitulate Regional Specific Genetic Programs and a Role for cAMP in Lineage Specification.Cellular and molecular gastroenterology and hepatology · 2025Article
- Article
- The application of organoids in cancers associated with pathogenic infections.Clinical and experimental medicine · 2024Review
- Reprogramming human urine cells into intestinal organoids with long-term expansion ability and barrier function.Heliyon · 2024Article
- Azoxymethane-induced carcinogenesis-like model of mouse intestine and mouse embryonic stem cell-derived intestinal organoids.Molecular biology reports · 2024Article
- Advanced 3D imaging and organoid bioprinting for biomedical research and therapeutic applications.Advanced drug delivery reviews · 2024Review
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Aditya MithalCenter for Regenerative Medicine of Boston University and Boston Medical Center, 670 Albany Street, Boston, MA, 02118, USA.ORCID http://orcid.org/0000-0002-8165-7674
Amalia CapillaCenter for Regenerative Medicine of Boston University and Boston Medical Center, 670 Albany Street, Boston, MA, 02118, USA.ORCID http://orcid.org/0000-0002-9546-9818
Dar HeinzeCenter for Regenerative Medicine of Boston University and Boston Medical Center, 670 Albany Street, Boston, MA, 02118, USA.ORCID http://orcid.org/0000-0003-1683-1178
Andrew BericalCenter for Regenerative Medicine of Boston University and Boston Medical Center, 670 Albany Street, Boston, MA, 02118, USA.
Carlos Villacorta-MartinCenter for Regenerative Medicine of Boston University and Boston Medical Center, 670 Albany Street, Boston, MA, 02118, USA.
Marall VedaieCenter for Regenerative Medicine of Boston University and Boston Medical Center, 670 Albany Street, Boston, MA, 02118, USA.
Anjali JacobCenter for Regenerative Medicine of Boston University and Boston Medical Center, 670 Albany Street, Boston, MA, 02118, USA.
Kristine AboCenter for Regenerative Medicine of Boston University and Boston Medical Center, 670 Albany Street, Boston, MA, 02118, USA.ORCID http://orcid.org/0000-0003-3626-705X
Aleksander SzymaniakCystic Fibrosis Foundation Therapeutics Lab, 44 Hartwell Avenue, Lexington, MA, 02421, USA.
Megan PeasleyCystic Fibrosis Foundation Therapeutics Lab, 44 Hartwell Avenue, Lexington, MA, 02421, USA.
Alexander StufferCystic Fibrosis Foundation Therapeutics Lab, 44 Hartwell Avenue, Lexington, MA, 02421, USA.
John MahoneyCystic Fibrosis Foundation Therapeutics Lab, 44 Hartwell Avenue, Lexington, MA, 02421, USA.
Darrell N KottonCenter for Regenerative Medicine of Boston University and Boston Medical Center, 670 Albany Street, Boston, MA, 02118, USA.
Finn HawkinsCenter for Regenerative Medicine of Boston University and Boston Medical Center, 670 Albany Street, Boston, MA, 02118, USA.ORCID http://orcid.org/0000-0002-2246-6448
Gustavo MostoslavskyCenter for Regenerative Medicine of Boston University and Boston Medical Center, 670 Albany Street, Boston, MA, 02118, USA. gmostosl@bu.edu.ORCID http://orcid.org/0000-0002-0784-2169
Funding
Project-005UL1TR001430 · NCATS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI BAIR-MERRITT, MEGAN H, CENTER, DAVID M. · 2015 to 2024
$52.3MBIOLOGY OF THE LUNG--MULTIDISCIPLINARY PROGRAMT32HL007035 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Darrell N. Kotton, JOSEPH P MIZGERD · 1985 to 2026
$24.3MDerivation of Transplantable Lung Epithelial Progenitors from iPS CellsR01HL095993 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Darrell N. Kotton · 2009 to 2026
$7.5MA National iPS Cell Network with Deep Phenotyping for Translational ResearchU01TR001810 · NCATS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI GILAD, YOAV, KOTTON, DARRELL N. · 2016 to 2020
$4.4MNRSA Training CoreTL1TR001410 · NCATS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI KOTTON, DARRELL N. · 2015 to 2024
$4.3MTraining Program in Cardiovascular Biology: Pre-DoctoralT32HL007969 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI RAVID, KATYA · 2003 to 2019
$3.2MA National Resource for Lung disease-specific iPS cellsR24HL123828 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI KOTTON, DARRELL N., MOSTOSLAVSKY, GUSTAVO · 2014 to 2018
$2.7MThe Role of Interferon Regulatory Factor 5 in the Pathogenesis of SLER01AI130199 · NIAID · BOSTON MEDICAL CENTER · PI RIFKIN, IAN R · 2017 to 2021
$2.6MEpigenenomic and transcriptomic networks in normal and defective lung developmentR01HL128172 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI KOTTON, DARRELL N. · 2015 to 2018
$2.2MiPSC-Derived Airway Basal Cells to Model Human Airway Development and DiseaseR01HL139799 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI HAWKINS, FINN · 2018 to 2022
$2.1MModeling prion diseases using human iPSC-derived neuronsR21NS111499 · NINDS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI HARRIS, DAVID A, MOSTOSLAVSKY, GUSTAVO · 2019 to 2019
$488kPluripotent stem cell modeling of children's interstitial lung diseaseF31HL134274 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI JACOB, ANJALI · 2016 to 2016
$22kNCATS NIH HHS TL1 TR001410NCATS NIH HHS U01 TR001810NCATS NIH HHS UL1 TR001430NHLBI NIH HHS R01 HL095993NHLBI NIH HHS R01 HL128172NHLBI NIH HHS R01 HL139799NHLBI NIH HHS R24 HL123828NHLBI NIH HHS T32 HL007035NHLBI NIH HHS T32 HL007969NIAID NIH HHS R01 AI130199NINDS NIH HHS R21 NS111499
Abstract
Efficient generation of human induced pluripotent stem cell (hiPSC)-derived human intestinal organoids (HIOs) would facilitate the development of in vitro models for a variety of diseases that affect the gastrointestinal tract, such as inflammatory bowel disease or Cystic Fibrosis. Here, we report a directed differentiation protocol for the generation of mesenchyme-free HIOs that can be primed towards more colonic or proximal intestinal lineages in serum-free defined conditions. Using a CDX2
Indexed as
CDX2 Transcription FactorCell DifferentiationCystic FibrosisEpithelial CellsGene Knock-In TechniquesGenetic VectorsHumansInduced Pluripotent Stem CellsIntestinesIntestine, SmallMesodermOrganoidsThyroid Nuclear Factor 1CDX2 protein, humanCDX2 Transcription FactorNKX2-1 protein, humanThyroid Nuclear Factor 1
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.